Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

    Virtual Booth

    Contact Supplier

    Coral

    Virtual Booth

    Contact Supplier

    ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

    Virtual Booth

    Contact Supplier

    Menu

    Volanesorsen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1TEGSEDI and WAYLIVRA revenue, net

    02 3Tegsedi and Waylivra Revenue, Net

    03 4Waylivra

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Waylivra

    Inotersen, Volanesorsen

    arrow
    PREP
    Not Confirmed

    Brand Name : Waylivra

    Sweden
    arrow
    PREP
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Inotersen, Volanesorsen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 13

    2020 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : TEGSEDI and WAYLIVRA revenue, net

    Inotersen, Volanesorsen

    arrow
    PREP
    Not Confirmed

    Brand Name : TEGSEDI and WAYLIVRA revenue, net

    U.S.A
    arrow
    PREP
    Not Confirmed

    Ionis Pharmaceuticals

    Inotersen, Volanesorsen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 56

    2020 Revenue in Millions : 70

    Growth (%) : -21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tegsedi and Waylivra Revenue, Net

    Inotersen, Volanesorsen

    arrow
    PREP
    Not Confirmed

    Brand Name : Tegsedi and Waylivra Revenue, Net

    U.S.A
    arrow
    PREP
    Not Confirmed

    Ionis Pharmaceuticals

    Inotersen, Volanesorsen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 30

    2021 Revenue in Millions : 56

    Growth (%) : -46

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Waylivra

    Inotersen, Volanesorsen

    arrow
    PREP
    Not Confirmed

    Brand Name : Waylivra

    Sweden
    arrow
    PREP
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Inotersen, Volanesorsen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 14

    2021 Revenue in Millions : 13

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Tegsedi and Waylivra Revenue, Net

    Inotersen, Volanesorsen

    arrow
    PREP
    Not Confirmed

    Brand Name : Tegsedi and Waylivra Revenue, Net

    U.S.A
    arrow
    PREP
    Not Confirmed

    Ionis Pharmaceuticals

    Inotersen, Volanesorsen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 35

    2022 Revenue in Millions : 30

    Growth (%) : 16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Waylivra

    Inotersen, Volanesorsen

    arrow
    PREP
    Not Confirmed

    Brand Name : Waylivra

    Sweden
    arrow
    PREP
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Inotersen, Volanesorsen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 20

    2022 Revenue in Millions : 14

    Growth (%) : 39

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Waylivra

    Inotersen, Volanesorsen

    arrow
    PREP
    Not Confirmed

    Brand Name : Waylivra

    Sweden
    arrow
    PREP
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Inotersen, Volanesorsen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2024 Revenue in Millions : 27

    2023 Revenue in Millions : 20

    Growth (%) : 34

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Tegsedi and Waylivra Revenue, Net

    Inotersen, Volanesorsen

    arrow
    PREP
    Not Confirmed

    Brand Name : Tegsedi and Waylivra Revenue, Net

    U.S.A
    arrow
    PREP
    Not Confirmed

    Ionis Pharmaceuticals

    Inotersen, Volanesorsen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2024 Revenue in Millions : 34

    2023 Revenue in Millions : 35

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF